Mechanism-Based Inhibition of Human Cytochrome P450 2B6 by Ticlopidine, Clopidogrel, and the Thiolactone Metabolite of Prasugrel
Authors:
- Yumi NishiyaYNYumi Nishiya
- Katsunobu HagiharaKHKatsunobu Hagihara
- Takashi ItoTITakashi Ito
- Masami TajimaMTMasami Tajima
- Shin-Ichi MiuraSMShin-Ichi Miura
- Atsushi KuriharaAKAtsushi Kurihara
- Nagy A. FaridNFNagy A. Farid
- Toshihiko IkedaTIToshihiko Ikeda
- 1 March 2009
- journal article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 37 (3) , 589-593
Abstract
Mechanism-based inhibition of CYP2B6 in human liver microsomes by thienopyridine antiplatelet agents ticlopidine and clopidogrel and the thiolactone metabolites of those two agents plus that of prasugrel were investigated by determining the time- and concentration-dependent inhibition of the activity of bupropion hydroxylase as the typical CYP2B6 activity. By comparing the ratios of kinact (maximal inactivation rate constant)/KI (the inactivator concentration producing a half-maximal rate of inactivation), it was found that the thiolactone metabolite of prasugrel is 10- and 22-fold less potent, respectively, in the mechanism-based inhibition of CYP2B6 than ticlopidine and clopidogrel. The kinact/KI ratio of the thiolactone metabolite of ticlopidine was comparable with that of the parent compound, whereas this ratio for the thiolactone metabolite of clopidogrel was significantly smaller than that of clopidogrel. In conclusion, ticlopidine, its thiolactone metabolite, and clopidogrel were more potent mechanism-based inhibitors of CYP2B6 than the thiolactone metabolite of prasugrel.Keywords
This publication has 29 references indexed in Scilit:
- Comparison of Human Cytochrome P450 Inhibition by the Thienopyridines Prasugrel, Clopidogrel, and TiclopidineDrug Metabolism and Pharmacokinetics, 2008
- Prasugrel, a New Thienopyridine Antiplatelet Drug, Weakly Inhibits Cytochrome P450 2B6 in HumansThe Journal of Clinical Pharmacology, 2008
- The Disposition of Prasugrel, a Novel Thienopyridine, in HumansDrug Metabolism and Disposition, 2007
- A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formationAmerican Heart Journal, 2007
- Interpatient variability in the pharmacokinetics of the HIV non‐nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphismBritish Journal of Clinical Pharmacology, 2005
- CHARACTERIZATION OF NOVEL DIHYDROTHIENOPYRIDINIUM AND THIENOPYRIDINIUM METABOLITES OF TICLOPIDINE IN VITRO: ROLE OF PEROXIDASES, CYTOCHROMES P450, AND MONOAMINE OXIDASESDrug Metabolism and Disposition, 2004
- Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270Blood, 2003
- Ticlopidine as a Selective Mechanism-Based Inhibitor of Human Cytochrome P450 2C19Biochemistry, 2001
- THE ROLE OF CYP2B6 IN HUMAN XENOBIOTIC METABOLISM*Drug Metabolism Reviews, 1999
- Clinical Pharmacokinetics of TiclopidineClinical Pharmacokinetics, 1994